COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

Request for Proposals (RFP S18-012) for Production of Affinity Binders

The National Cancer Institute Office of Cancer Clinical Proteomics Research, through its prime contract with Leidos Biomedical Research Inc. (Leidos Biomed), seeks proposals in accordance with the requirements for the Request for Proposals (RFP S18-012) for production of Affinity Binders in support of the NCI's Antibody Characterization Program.  Leidos Biomed is the Operations and Technical Support Services Contractor at the Frederick National Laboratory for Cancer research and is responsible for awarding an agreement in support of this effort.

NCI's Antibody Characterization Program improves reproducibility in biomedical research by providing well-characterized and analytically validated renewable affinity reagents with unique specificities/functions for fit for purpose applications, including supporting resources (standard operating procedures) to the scientific community.

To request a copy of RFP S18-012 or for additinal informationclarification and clarification, please contact , please contact Kayla Williams ( No Later than 12 PM (ET) on Thursday, November 2, 2017. All Offers Must be Received by 12 PM (ET) on Monday, November 20, 2017.

Please forward this message to colleagues who may be interested in this funding opportunity.